The first study to show the effectiveness of checkpoint blockade in relapsed hematological malignancies after allo-HSCT was a phase I/Ib clinical trial, which examined the use of CTLA-4 inhibition, specifically using ipilimumab, on patients with relapsed hematological malignancies following allo-HSCT. The gene discussed is CTLA4; the disease is hematologic disorder.